

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 1 of 2

**Complete if Known**

<b>Application Number</b>	<b>09/531,969</b>
---------------------------	-------------------

**09/531,969**

<b>Filing Date</b>	<b>March 21, 2000</b>
--------------------	-----------------------

**March 21, 2000**

<b>First Named Inventor</b>	<b>Jan Geliebter</b>
-----------------------------	----------------------

**Jan Geliebter**

Art Unit	1632
----------	------

1632

Examiner Name	Peter Paras, Jr.
---------------	------------------

**Peter Paras, Jr.**

Attorney Docket Number	96700/596
------------------------	-----------

96700/596

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner  
Signature**

Pete Parag


Date Considered

8/5/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Business Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+ MAY 23 2003

RECEIVED

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

### Complete if Known

Application Number	09/531,969
Filing Date	March 21, 2000
First Named Inventor	Jan Geliebter
Group Art Unit	1632 1633
Examiner Name	Peter Paras, Jr. Robert M. Kelly
Attorney Docket Number	96700/596

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
PK	3	Channon, Keith M., et al., Adenoviral gene transfer of nitric oxide synthase: High level expression in human vascular cells, Cardiovascular Research 32 (1996) 962-972	
	4	Fan, SF et al. BIOSIS Accession No. PREV199598178283, An analysis of the maxi-K+ (K-CA) channel in cultured human corporal smooth muscle cells. J. Urology 153: 818-825, 1995 [Abstract Only]	
	5	Bredt, David S, Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase, Nature 351 (1991) 714-718	
	6	Magee, T et al. Cloning of a Novel Neuronal Nitric Oxide Synthase Expressed in Penis and Lower Urinary Tract, Biochemical Biophysical Res. Commun. 226 (1996) 145-151	
	7	Kim, Young Chan et al. CA Accession No. 122:77664 HCA, Experimental evidence for endothelium dependent relaxation and neuronal nitric oxide in corpus cavernosum, Yonsei Medical Journal 35(3): 308-13, 1994 [Abstract only]	
	8	Mills, TM et al. MEDLINE Accession No. NLM8735191, Sites of androgenic regulation of cavernosal blood pressure during penile erection in the rat, International Journal of Impotence Research 8: 29-34, 1996 [Abstract Only]	
	9	Christ, GJ et al. MEDLINE Accession No. NLM7688635, The role of gap junctions and ion channels in the modulation of electrical and chemical signals in human corpus cavernosum smooth muscle, Intern. J. Impotence Res. 5: 77-93, 1993 [Abstract Only]	
PK	10	Melman, A et al. The Successful Long-Term Treatment of Age Related Erectile Dysfunction with HSLO CDNA in Rats in Vivo, The Journal of Urology, Vol. 170, July 2003 (In Press)	

Examiner  
Signature


Date  
Considered

8/8/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete If Known**

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Application Number	09/531,969
Filing Date	March 21, 2000
First Named Inventor	Jan Geliebter
Art Unit	1632
Examiner Name	Peter Paras, Jr. Robert M. Kelly
Attorney Docket Number	96700/596

## U. S. PATENT DOCUMENTS

[illegible]

**FOREIGN PATENT DOCUMENTS**

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T*
		Country Code* Number* Kind Code* (if known)				
JAK JLB	1	WO 98/33905	08-06-1998	Isis Innovation Ltd.		
	2	WO 97/18308	05-22-1997	The Wellcome Trust		
					Ltd. as Trustee of the Wellcome Trust	

**Examiner  
Signature**

Date	Considered
10/1/80	10/1/80
10/2/80	10/2/80
10/3/80	10/3/80
10/4/80	10/4/80
10/5/80	10/5/80
10/6/80	10/6/80
10/7/80	10/7/80
10/8/80	10/8/80
10/9/80	10/9/80
10/10/80	10/10/80
10/11/80	10/11/80
10/12/80	10/12/80
10/13/80	10/13/80
10/14/80	10/14/80
10/15/80	10/15/80
10/16/80	10/16/80
10/17/80	10/17/80
10/18/80	10/18/80
10/19/80	10/19/80
10/20/80	10/20/80
10/21/80	10/21/80
10/22/80	10/22/80
10/23/80	10/23/80
10/24/80	10/24/80
10/25/80	10/25/80
10/26/80	10/26/80
10/27/80	10/27/80
10/28/80	10/28/80
10/29/80	10/29/80
10/30/80	10/30/80
10/31/80	10/31/80

12/16/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**



PTO/SB/08B (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

2

### Complete if Known

Application Number	09/531,969
Filing Date	March 21, 2000
First Named Inventor	Jan Geliebter
Art Unit	1632
Examiner Name	Peter Pares, Jr. Robert M. Kelly
Attorney Docket Number	96700/596

### NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
RUK	3	HUARD J. ET AL., entitled "Myoblast injection into the Bladder Wall: A Possible Method of Modulating Detrusor Contractility and Cell-Mediated Gene Therapy for Bladder Dysfunction," Journal of Urology, Vol. 159, No. 5, May 30, 1998., page 16, abstract XP002420820, Abstract.	
	4	CARVALHO A.C. ET AL., entitled "Gap Junctions Formed of Connexin 43 are Found Between Smooth Muscle Cells of Human Corpus Cavernosum," Journal of Urology, Vol. 149, No. 6, 1993, pgs. 1568-1575, XP002273927, Abstract.	
	5	MORENO A. P. ET AL., entitled "Gap Junctions Between Human Corpus Cavernosum Smooth Muscle Cells: Gating Properties and Unitary Conductance," American Journal of	
	6	GROSSMAN H. ET AL., entitled "Decreased Connexin Expression and Intercellular Communication in Human Bladder Cancer Cells," Cancer Research, Vol. 54, No. 11, 1994, pgs. 3062-3065.	
	7	SIEMER C. ET AL., entitled "Characterization of Maxi K Channels in Smooth Muscle Cells From Rat Urinary Bladder," Pfluegers Archiv European Journal of Physiology, Vol. 434, No. 5 Suppl., 1997, p. R102, XP008028610, Abstract.	
	8	DAMASER M. S. ET AL., entitled "Calcium Regulation of Urinary Bladder Function," Journal of Urology, Vol. 157, No. 2, 1997, pgs. 732-738, XP002282784, Abstract.	
RUK	9	LEVIN R.M. ET AL., entitled "Etiology of Bladder Dysfunction Secondary to Partial Outlet Obstruction. Calcium Disregulation in Bladder Power Generation and the Ability to Perform Work," Scandinavian Journal of Urology and Nephrology Supplementum, Vol. 0, No. 184, 1997, pgs. 43-50, XP002262765, Abstract.	
RUK		No. 184, 1997, pg 43-50, Abstract	

Examiner Signature	<i>R. M. Kelly</i>	Date Considered	12/16/04
--------------------	--------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)  
Approved for use through 07/31/2008. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/531,969		
		Filing Date	March 21, 2000		
		First Named Inventor	Jan Geliebter		
		Art Unit	1632		
		Examiner Name	Robert M. Kelly		
Sheet	X 1	of	X 1	Attorney Docket Number	96700/596

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
RMK	3	HUARD, J. et al. Myoblast injection into the Bladder Wall: A Possible Method of Modulating Detrusor Contractility and Cell-Mediated Gene Therapy for Bladder Dysfunction. Journal of Urology, Vol. 159, No. 5, May 30, 1998, page 16, Abstract.	
RMK	4	CARVALHO A C DE CAMPOS, et al.. Gap Junctions Formed of Connexin 43 are Found Between Smooth Muscle Cells of Human Corpus Cavemosum. Journal of Urology, Vol. 149, No. 6, 1993, pgs. 1568-1575, Abstract.	
	5	MORENO, A.P. et al. Gap Junctions Between Human Corpus Cavemosum Smooth Muscle Cells: Gating Properties and Unitary Conductance. American Journal of Physiology, Vol. 264, No. 1 Part 1, 1993, pgs. C80-C92, Abstract.	
	6	GROSSMAN, B.H. et al. Decreased Connexin in Expression and Intercellular Communication in Human Bladder Cancer Cells. Cancer Research, Vol. 54, No. 11, 1994, pgs. 3062-3065.	
	7	SIEMER, P. et al. Characterization of Maxi K Channels in Smooth Muscle Cells From Rat Urinary Bladder. Pflügers Archiv European Journal of Physiology, Vol. 434, No. 5 Suppl., 1997, p. R102, Abstract.	
	8	DAMASER, M.S. et al. Calcium Regulation of Urinary Bladder Function. Journal of Urology 157(2): 732-8, 1997, Abstract.	
RMK	9	LEVIN, R.M. et al. Etiology of Bladder Dysfunction Secondary to Partial Outlet Obstruction. Calcium Disregulation in Bladder Power Generation and the Ability to Perform Work. Scand. J. Urol. Nephrol. Suppl., No. 184, 1997, pgs. 43-50, Abstract	

Examiner Signature	Robert M. Kelly	Date Considered	4/14/05
--------------------	-----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.